Ingevity (NGVT) has drawn fresh attention after reporting first quarter 2026 results, with sales of US$258 million and net income of US$59.8 million, compared to US$247.9 million and US$20.5 million a year earlier.

The earnings release appears to have been a key catalyst for the recent share price move, with a 10.49% 1 month share price return and a 29.59% year to date share price return. The 1 year total shareholder return of 98.5% points to strong momentum over a longer period.

If you are looking for other ideas after reviewing Ingevity, this could be a good moment to broaden your search with 34 power grid technology and infrastructure stocks

With the stock returning 99% over the past year and trading close to its US$80.50 analyst price target, yet screening as materially below one estimate of intrinsic value, the key question is clear: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 3.3% Undervalued

Against the last close of $77.87, the most followed narrative points to a fair value of $80.50, framing Ingevity as modestly undervalued on discounted cash flows.

Accelerated portfolio repositioning and the advanced-stage divestiture of non-core, lower-margin businesses (Industrial Specialties and CTO refinery) are expected to drive a step change in margin profile. This is described as enabling greater focus and capital allocation toward higher-growth, value-added specialty chemicals, supporting both revenue quality and sustained EBITDA margin improvement.

Want to see what sits behind that margin reset and cash flow story? The narrative leans on specific revenue, margin and valuation assumptions that could surprise you.

Result: Fair Value of $80.50 (UNDERVALUED)

However, the APT goodwill impairment charge, along with ongoing tariff related pressure in key industrial markets, could still disrupt margins and weaken the underlying earnings story.

Another View: Multiples Tell a Different Story

The DCF-based fair value suggests Ingevity could be materially undervalued, yet the current P/S of 2.3x looks rich next to the US Chemicals industry at 1.1x, peers at 1.2x, and even a fair ratio of 1.6x. If the market shifts closer to that fair ratio, how comfortable are you with the valuation risk?

Next Steps

With the story pulling in different directions on valuation, risks and rewards, this is a good time to check the data yourself and decide where you stand. You can start with 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

Once you have formed a view on Ingevity, do not stop there. Broaden your opportunity set now so you are not relying on a single stock story.

• Target potential mispricings by scanning companies that score well on quality metrics and valuation using the 44 high quality undervalued stocks.
• Strengthen your income stream by focusing on companies with robust payout profiles through the 12 dividend fortresses.
• Prioritise financial resilience by filtering for companies with durable balance sheets and solid fundamentals in the solid balance sheet and fundamentals stocks screener (45 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.